Why FDA Said No to a Melanoma Drug - Summary - MDSpire
FDA & Government News

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

  • By

  • Arthur Allen

  • May 15, 2026

  • 9 min

Share

The FDA's rejection of the melanoma treatment RP1, which showed life-prolonging effects in clinical trials, has left oncologists and patients devastated. Doctors like Trisha Wise-Draper express concern for the 2,000 patients reliant on such innovations. Despite promising results, FDA officials cited procedural concerns surrounding the trial's design, leading to doubts about the approval process under the recent administration. With approximately 112,000 new melanoma cases annually, the fallout from this decision has serious implications for drug development and trust in regulatory standards.

Original Source(s)

Why FDA Said No to a Melanoma Drug

  • by Arthur Allen

  • May 15, 2026

Related Content

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

AOPT Plus Collagen May Ease Rosacea

Randomized trial suggests better short-term outcomes and lower recurrence at 24 weeks